In vivo studies clearly demonstrated that the inhibition of SLO activity was significantly associated with a disease severity reduction in necrotizing fasciitis, necrotizing myositis, bacteremia, and soft tissue infection models (54, 55). This evidence concerns the gene KCNMA1 and fasciitis.